 Kathleen Packard
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Health Occupations | 2 | 2019 | 37 | 0.680 |
Why?
| | Fish Oils | 1 | 2019 | 26 | 0.580 |
Why?
| | Interprofessional Relations | 2 | 2019 | 281 | 0.580 |
Why?
| | Education, Distance | 1 | 2019 | 61 | 0.570 |
Why?
| | Cardiovascular Agents | 2 | 2016 | 164 | 0.550 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2019 | 142 | 0.540 |
Why?
| | Simulation Training | 1 | 2019 | 134 | 0.510 |
Why?
| | Medication Adherence | 3 | 2016 | 539 | 0.510 |
Why?
| | Secondary Prevention | 3 | 2016 | 255 | 0.490 |
Why?
| | Aspirin | 2 | 2016 | 400 | 0.470 |
Why?
| | Patient Safety | 1 | 2019 | 349 | 0.470 |
Why?
| | Acute Coronary Syndrome | 3 | 2014 | 293 | 0.430 |
Why?
| | Rhabdomyolysis | 1 | 2014 | 24 | 0.410 |
Why?
| | Pharmacists | 2 | 2014 | 240 | 0.380 |
Why?
| | Medication Reconciliation | 1 | 2012 | 31 | 0.350 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 214 | 0.350 |
Why?
| | Coronary Artery Bypass | 3 | 2004 | 269 | 0.350 |
Why?
| | Professional Role | 2 | 2014 | 158 | 0.350 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2014 | 497 | 0.340 |
Why?
| | Cardiac Rehabilitation | 1 | 2012 | 46 | 0.340 |
Why?
| | Coronary Disease | 2 | 2004 | 386 | 0.330 |
Why?
| | Education, Pharmacy | 1 | 2010 | 121 | 0.280 |
Why?
| | Atrial Fibrillation | 4 | 2011 | 550 | 0.260 |
Why?
| | Angiotensin Receptor Antagonists | 3 | 2010 | 114 | 0.260 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2010 | 250 | 0.240 |
Why?
| | Heart Failure | 3 | 2014 | 2323 | 0.230 |
Why?
| | Patient Care Team | 1 | 2012 | 689 | 0.230 |
Why?
| | Coronary Artery Disease | 1 | 2012 | 741 | 0.230 |
Why?
| | Thrombosis | 2 | 2012 | 393 | 0.210 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2171 | 0.210 |
Why?
| | Calcium Channel Blockers | 3 | 2010 | 165 | 0.210 |
Why?
| | Losartan | 1 | 2004 | 13 | 0.210 |
Why?
| | Nail Diseases | 1 | 2004 | 9 | 0.210 |
Why?
| | Hospitalization | 2 | 2014 | 2434 | 0.210 |
Why?
| | Cholesterol, HDL | 1 | 2005 | 200 | 0.210 |
Why?
| | Angiotensin II | 1 | 2004 | 97 | 0.200 |
Why?
| | Graft Occlusion, Vascular | 1 | 2004 | 42 | 0.200 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1563 | 0.200 |
Why?
| | Histamine | 1 | 2003 | 53 | 0.200 |
Why?
| | Diltiazem | 1 | 2003 | 17 | 0.190 |
Why?
| | Gemfibrozil | 1 | 2002 | 9 | 0.190 |
Why?
| | Propanolamines | 1 | 2003 | 40 | 0.190 |
Why?
| | Fenofibrate | 1 | 2002 | 28 | 0.190 |
Why?
| | Polyuria | 1 | 2002 | 2 | 0.190 |
Why?
| | Th1 Cells | 1 | 2003 | 139 | 0.190 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2010 | 222 | 0.180 |
Why?
| | Th2 Cells | 1 | 2003 | 171 | 0.180 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 96 | 0.180 |
Why?
| | Bronchial Diseases | 1 | 2002 | 38 | 0.180 |
Why?
| | Piperazines | 3 | 2014 | 381 | 0.180 |
Why?
| | Lactones | 1 | 2002 | 58 | 0.180 |
Why?
| | Hyperlipidemias | 1 | 2002 | 122 | 0.180 |
Why?
| | Edema | 1 | 2002 | 124 | 0.170 |
Why?
| | Anti-Obesity Agents | 1 | 2002 | 66 | 0.170 |
Why?
| | Constipation | 1 | 2002 | 98 | 0.170 |
Why?
| | Asthma | 2 | 2003 | 1768 | 0.170 |
Why?
| | Tissue Plasminogen Activator | 1 | 2003 | 244 | 0.170 |
Why?
| | Fibrinolytic Agents | 1 | 2003 | 292 | 0.160 |
Why?
| | Students, Pharmacy | 2 | 2012 | 96 | 0.160 |
Why?
| | Smoking Cessation | 1 | 2004 | 439 | 0.150 |
Why?
| | Nursing Evaluation Research | 1 | 2019 | 44 | 0.150 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1371 | 0.150 |
Why?
| | Nursing Education Research | 1 | 2019 | 43 | 0.150 |
Why?
| | Education, Nursing, Graduate | 1 | 2019 | 40 | 0.150 |
Why?
| | Eicosapentaenoic Acid | 1 | 2019 | 36 | 0.140 |
Why?
| | Drug Interactions | 4 | 2015 | 401 | 0.140 |
Why?
| | Humans | 26 | 2019 | 144957 | 0.140 |
Why?
| | Renal Dialysis | 1 | 2003 | 462 | 0.140 |
Why?
| | Docosahexaenoic Acids | 1 | 2019 | 83 | 0.140 |
Why?
| | Medical Errors | 1 | 2019 | 118 | 0.140 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 965 | 0.140 |
Why?
| | Students, Nursing | 1 | 2019 | 90 | 0.130 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 598 | 0.120 |
Why?
| | Smoking | 1 | 2004 | 1472 | 0.120 |
Why?
| | Perception | 1 | 2019 | 377 | 0.120 |
Why?
| | Prasugrel Hydrochloride | 2 | 2014 | 22 | 0.120 |
Why?
| | Cytokines | 1 | 2003 | 2065 | 0.110 |
Why?
| | Thiophenes | 2 | 2014 | 128 | 0.110 |
Why?
| | Pharmaceutical Services | 2 | 2014 | 78 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 923 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 576 | 0.110 |
Why?
| | Male | 13 | 2019 | 72406 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2016 | 11695 | 0.100 |
Why?
| | Cardiovascular System | 1 | 2015 | 138 | 0.100 |
Why?
| | Acetanilides | 1 | 2013 | 11 | 0.100 |
Why?
| | Sodium Channel Blockers | 1 | 2013 | 24 | 0.100 |
Why?
| | Adenosine | 2 | 2014 | 255 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2004 | 2920 | 0.100 |
Why?
| | Qualitative Research | 2 | 2019 | 1671 | 0.100 |
Why?
| | Antidepressive Agents | 1 | 2015 | 248 | 0.100 |
Why?
| | Angina Pectoris | 1 | 2013 | 75 | 0.100 |
Why?
| | Female | 13 | 2019 | 78376 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1135 | 0.100 |
Why?
| | Affect | 1 | 2015 | 318 | 0.090 |
Why?
| | Body Temperature | 1 | 2014 | 229 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1054 | 0.090 |
Why?
| | United States | 4 | 2019 | 15988 | 0.090 |
Why?
| | Interdisciplinary Studies | 1 | 2012 | 29 | 0.090 |
Why?
| | Risk Factors | 3 | 2016 | 10792 | 0.090 |
Why?
| | Health Occupations | 1 | 2012 | 36 | 0.090 |
Why?
| | Health Resources | 1 | 2013 | 130 | 0.090 |
Why?
| | Imines | 1 | 2012 | 6 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 350 | 0.090 |
Why?
| | Aged | 8 | 2014 | 25947 | 0.090 |
Why?
| | Professional Competence | 1 | 2012 | 98 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 2 | 2010 | 609 | 0.090 |
Why?
| | Medication Errors | 1 | 2012 | 83 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1048 | 0.080 |
Why?
| | Hospitals, Private | 1 | 2010 | 12 | 0.080 |
Why?
| | Hemorrhage | 2 | 2014 | 809 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 465 | 0.080 |
Why?
| | Sotalol | 2 | 2010 | 13 | 0.070 |
Why?
| | Amiodarone | 2 | 2010 | 31 | 0.070 |
Why?
| | Intracranial Hemorrhages | 1 | 2009 | 100 | 0.070 |
Why?
| | California | 1 | 2010 | 475 | 0.070 |
Why?
| | Warfarin | 1 | 2009 | 170 | 0.070 |
Why?
| | Postoperative Period | 2 | 2010 | 354 | 0.070 |
Why?
| | Pyridines | 1 | 2012 | 605 | 0.070 |
Why?
| | Educational Measurement | 1 | 2010 | 326 | 0.060 |
Why?
| | Amlodipine | 1 | 2006 | 9 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 732 | 0.060 |
Why?
| | Hypertension | 2 | 2006 | 1264 | 0.060 |
Why?
| | Middle Aged | 6 | 2014 | 35928 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2010 | 511 | 0.060 |
Why?
| | Anticoagulants | 1 | 2011 | 724 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 50 | 0.060 |
Why?
| | Valine | 1 | 2006 | 80 | 0.060 |
Why?
| | Adult | 5 | 2014 | 40506 | 0.060 |
Why?
| | Depression | 1 | 2015 | 1559 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2010 | 780 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2009 | 529 | 0.050 |
Why?
| | Hyperemia | 1 | 2005 | 49 | 0.050 |
Why?
| | India | 1 | 2005 | 218 | 0.050 |
Why?
| | Cross-Over Studies | 2 | 2006 | 601 | 0.050 |
Why?
| | Toes | 1 | 2004 | 16 | 0.050 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2004 | 142 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2003 | 24 | 0.050 |
Why?
| | Brachial Artery | 1 | 2005 | 206 | 0.050 |
Why?
| | Fingers | 1 | 2004 | 107 | 0.050 |
Why?
| | Probability | 1 | 2004 | 312 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Vascular Patency | 1 | 2003 | 121 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2002 | 11 | 0.050 |
Why?
| | Equipment Failure | 1 | 2003 | 115 | 0.050 |
Why?
| | Triglycerides | 1 | 2005 | 521 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 189 | 0.040 |
Why?
| | Renin-Angiotensin System | 1 | 2002 | 78 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 2003 | 163 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 529 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1416 | 0.040 |
Why?
| | Vasodilation | 1 | 2005 | 523 | 0.040 |
Why?
| | Graft Survival | 1 | 2004 | 526 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1540 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2003 | 769 | 0.040 |
Why?
| | Prospective Studies | 2 | 2004 | 7997 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2004 | 299 | 0.040 |
Why?
| | Risk Assessment | 2 | 2015 | 3676 | 0.040 |
Why?
| | Counseling | 1 | 2004 | 408 | 0.040 |
Why?
| | Graft Rejection | 1 | 2004 | 540 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2013 | 5417 | 0.040 |
Why?
| | Sex Factors | 1 | 2005 | 2114 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2013 | 17101 | 0.030 |
Why?
| | Polypharmacy | 1 | 2015 | 93 | 0.030 |
Why?
| | Ranolazine | 1 | 2013 | 25 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2014 | 69 | 0.020 |
Why?
| | Young Adult | 1 | 2010 | 14126 | 0.020 |
Why?
| | Time Factors | 1 | 2003 | 7183 | 0.020 |
Why?
| | Risk | 1 | 2014 | 911 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2011 | 77 | 0.020 |
Why?
| | Patient Selection | 1 | 2015 | 719 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2011 | 117 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1660 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 2029 | 0.020 |
Why?
| | Digoxin | 1 | 2010 | 27 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2009 | 11 | 0.020 |
Why?
| | Signal Transduction | 1 | 2003 | 5233 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2010 | 139 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2032 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 124 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38109 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2014 | 543 | 0.020 |
Why?
| | Valsartan | 1 | 2006 | 32 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 38 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 439 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1209 | 0.010 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2004 | 197 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1769 | 0.010 |
Why?
|
|
Packard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|